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Background:The prothrombotic, hypofibrinolytic state that develops in patients with intermittent claudication (IC) upon
walking due to ischemia-reperfusion injury (IRI) of the leg muscles may contribute to the high incidence of life- and
limb-threatening thrombotic events observed in this patient group. Treatments, such as angioplasty, that obtund the IRI
also ameliorate the procoagulant diathesis. The effect on this diathesis of supervised exercise and cilostazol, both of which
provide symptomatic benefit in IC, but without significantly obtunding IRI, is unknown.
Methods: Thirty-four patients (27 men and 7 women; median age, 67 years; range, 63-72 years) were randomized to
receive best medical therapy (BMT) plus supervised exercise (n  9), BMT plus cilostazol (n  9), BMT plus
supervised exercise plus cilostazol (n 7), or BMT alone (n 9) in a 2 2 factorial design. Thrombin-antithrombin
complex and prothrombin fragments 1 and 2, both markers of thrombin generation; plasminogen activator inhibitor
antigen and tissue plasminogen activator antigen, both markers of fibrinolysis; ankle-brachial pressure index (ABPI); and
initial and absolute claudication distance (ACD) were measured at baseline and then 3 and 6months after randomization.
Results: At 6 months, when compared with receiving BMT only, supervised exercise and cilostazol resulted in improve-
ments in ABPI of 18% and 13% and in ACD of 40% and 64%, respectively. The effects on ABPI and ACD of combining
supervised exercise and cilostazol were additive. Supervised exercise, cilostazol, and supervised exercise combined with
cilostazol had no significant effect on any of the four hemostatic markers.
Conclusions: Treatment of IC by supervised exercise or cilostazol results in significant improvements in ABPI and ACD
but has no demonstrable effect on the prothrombotic diathesis. This suggests that supervised exercise and cilostazol,
unlike angioplasty, are unlikely to have a long-term beneficial effect on the thrombotic risks faced by these patients.
(J Vasc Surg 2007;45:65-70.)Intermittent claudication (IC) affects up to 5% of the
middle-aged white population.1 Although only a small minor-
ity of affected individuals will develop limb-threatening isch-
emia,2 when compared with an age- and sex-matched popu-
lation, claudicants exhibit a threefold to fourfold increase
(approximately 5%-10% per year) in thrombotic cardiovas-
cular events such acute coronary syndrome and ischemic
stroke.3,4 Previous work from our group has demonstrated
that individuals with IC exhibit a procoagulant diathesis
characterized by excessive thrombin generation and relative
hypofibrinolysis and that this diathesis is acutely exacer-
bated by exercise.5 We have hypothesized that this proco-
agulant diathesis results from ischemia-reperfusion injury
(IRI) of the leg muscles upon walking and that it contrib-
utes to the high incidence of thrombotic morbidity and
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doi:10.1016/j.jvs.2006.08.084mortality observed in this condition. This hypothesis is
supported by our recent observation that lower limb revas-
cularization by percutaneous balloon angioplasty results in
a medium-term improvement in the resting procoagulant
and hypofibrinolytic state.6
Supervised exercise therapy and cilostazol have both
previously been shown to result in significant improve-
ments in initial (ICD) and absolute (ACD) claudication
distance in subjects with IC.7-9 However, there is continu-
ing uncertainty with regard to the possible mechanisms
underlying these benefits, and there are only limited data
on their effects on hemostasis. The aim of this study was to
compare the effects of supervised exercise and cilostazol on
ICD and ACD; ankle-brachial pressure index (ABPI); and
thrombin generation and fibrinolysis in patients random-
ized within the INtermittent Claudication, EXercise, and
Cilostazol Trial (INEXACT).
METHODS
Local ethics committee approval was obtained, and all
patients provided written, fully informed consent. All pa-
tients referred to our unit from primary care or other
hospital specialties with a suspected diagnosis of IC were
reviewed in a dedicated, one-stop IC clinic. Subjects with
clinically confirmed IC (diagnosed by using the Edinburgh
Claudication Questionnaire10 and the finding of a reduced
ABPI [0.9] in the affected leg) were commenced on best
medical therapy (BMT) as previously described11 and
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evaluated for eligibility for randomization into INEXACT
according to the inclusion and exclusion criteria detailed in
Table I. Eligible subjects were randomized in a 2  2 factorial
design to continueBMTonly or to receive BMT supervised
exercise, BMT cilostazol, or BMT supervised exercise
cilostazol. The 2 2 factorial design is well recognized as one
of the most robust study designs and allows for greater inter-
rogation of the data, as well as allowing the interaction of
different treatments to be assessed.
The supervised exercise comprised a 3-month, twice-
weekly, 1-hour physiotherapist-led exercise program, as
previously described.6 In addition to the supervised ses-
sions, subjects were provided with a videotape of the exer-
cise program and encouraged to undertake the exercises at
home and complete an exercise log on the days that they
did not attend the classes. Cilostazol was prescribed at a
dose of 100mg twice daily. If side effects were encountered
(most commonly headache and diarrhea), the dosing regi-
men was halved for 1 week.
Subjects were assessed immediately after randomiza-
tion and at 3 and 6 months after randomization. Before
each visit, subjects were asked to refrain from smoking or
eating a heavy meal and to avoid unaccustomed exercise in
the preceding 24 hours. All visits took place between
8:30 AM and 9:00 AM, and subjects were transported to the
hospital by taxi and then transferred to the Vascular Inves-
tigation Unit by wheelchair to avoid walking. Subjects
rested for 60 minutes before undergoing venipuncture
from an antecubital fossa vein without tourniquet. Blood
was collected into sodium citrate tubes and was immedi-
ately centrifuged at 4°C for 15 minutes at 2000g. The
resultant plasma was stored at 80°C for later batch anal-
ysis. ABPI was measured in both legs by using a Mini
Dopplex with an 8-MHz probe (Huntleigh Diagnostics,
Table I. INEXACT trial inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Intermittent claudication* Significant aortoiliac disease
Maximum walking
distance 20-500 m
Unable to complete treadmill
assessment to ACD
Willing to participate MI, TIA, CVA, or PTCA in past
3 mo
GFR 20 mL/min†
Congestive heart failure
Known predisposition for bleeding
CYP3A4 or CYP2C19 inhibitor use‡
INEXACT, INtermittent Claudication, EXercise, and Cilostazol Trial;
ACD, absolute claudication distance;MI,myocardial Infarction; TIA, tran-
sient ischemic attack; CVA, cerebrovascular accident; PTCA, percutaneous
transluminal coronary angioplasty.
*Positive Edinburgh claudication questionnaire10 and ankle-brachial pres-
sure index less than 0.9 in the affected limb.
†Glomerular filtration rate (GFR) estimated by the modification of diet in
renal disease equation 7 (MDRD7).
‡For example, cimetidine, diltiazem, erythromycin, ketoconazole, lansopra-
zole, omeprazole, and human immunodeficiency virus 1 protease inhibitors.Cardiff, UK). For each leg, the highest recorded pressurefrom the three ankle vessels (anterior tibial, posterior tibial,
and perforating peroneal) was used to determine the ABPI.
Subjects then exercised by a standard treadmill exercise test
(3 km/h at a 10% incline) to their ACD or 1000 m (at
follow-up visits), whichever was soonest. The distance
when claudication pain was first perceived was recorded as
the ICD.
Studies of coagulation and fibrinolysis. Thrombin
generation cannot be directly measured because, under
pathologic conditions, less than 1% of circulating prothrom-
bin is transformed to thrombin, and it is rapidly inactivated
by antithrombin III. Thrombin generation can, however, be
measured indirectly by measuring the amount of inactivated
thrombin, namely, thrombin-antithrombin (TAT) complex,
and by measuring the cleavage products of prothrombin as
it is converted to thrombin, namely, prothrombin frag-
ments 1 and 2 (PF12).12 Plasma levels of TAT and PF12
(both Dade-Behring, Marburg, Germany) were determined
by enzyme-linked immunosorbent assay (ELISA). The anal-
ysis was manual except for the reading, which was performed
on an ELISA workstation (Triturus, Grifols, Cambridge,
UK).
Fibrinolytic function was examined by measuring plas-
minogen activator inhibitor (PAI)-1 antigen levels and
tissue plasminogen activator (t-PA) antigen and t-PA activ-
ity levels. A hypofibrinolytic state is associated with in-
creased PAI-1 and t-PA antigen levels and reduced t-PA
activity. PAI, t-PA antigen, and t-PA activity levels (all
Technoclone, Vienna, Austria) were determined by ELISA.
PAI activity was not measured, because we were unable to
find an activity assay that produced reproducible results. All
assays were performed by an accredited laboratory. Samples
were analyzed as one batch, and the intra-assay coefficient
of variation for all assays was less than 5%.
Sample size and statistical analysis. Statistical analy-
sis was performed by using SPSS 11.0 (SPSS Inc, Chicago, Ill)
on an intention-to-treat basis. Groups were compared at
baseline by using the analysis of variance (ANOVA) test for
continuous data and the Fisher exact test for categorical
data. Changes over time within groups were analyzed by
using the Wilcoxon signed rank test. The effect of treat-
ment among the four groups was examined by ANOVA by
using an additive General Linear Model. The combined
effect of supervised exercise and cilostazol was explored by
using a multiplicative General Linear Model. A P value
.05 was considered statistically significant. On the basis of
pilot data, 32 subjects were required to detect a 50%
reduction in TAT in the treatment groups with 80% power
and a P value of .05.
RESULTS
Overall, 38 subjects were randomized into this sub-
study of the INEXACT trial. Of these, four subjects with-
drew after randomization (three no longer wished to con-
tinue to participate in the trial, and one subject sustained a
fractured ankle unrelated to trial participation). The re-
maining 34 subjects (27 men and 7 women) were studied
up to 6 months after randomization (Table II). In total, 9
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vised exercise, and 16 to receive cilostazol in the 2  2
factorial design.
Six subjects encountered side effects with cilostazol;
three reported diarrhea and two headaches, all of which
responded to halving the treatment dose (100mg daily) for
1 week before returning to 100 mg twice daily. These side
effects have been previously described.
ABPI and claudication distance. The proportional
changes in ABPI, ICD, and ACD between baseline and 6
months and the overall effect of treatment compared with
receiving BMT alone are shown in Table III.
In subjects randomized to remain solely on BMT, there
was no significant change in ABPI (median [interquartile
range; IQR] ABPI at baseline, 3 months, and 6 months:
0.74 [0.68-0.92], 0.76 [0.60-0.90], and 0.74 [0.59-0.84];
P .138); however, those randomized to supervised exer-
cise (median [IQR] ABPI at baseline, 3 months, and 6
months: 0.67 [0.58-0.77], 0.79 [0.67-0.91], and 076
[0.67-0.92]; P  .005) and cilostazol (median [IQR]
ABPI at baseline, 3 months, and 6 months: 0.68 [0.56-
0.82], 0.80 [0.69-0.98], and 0.81 [0.66-0.93]; P  .048)
both showed small but significant improvements in ABPI.
ANOVA demonstrated that supervised exercise (P .001)
and cilostazol (P  .003) both resulted in significant im-
provements in ABPI when compared with no adjuvant
treatment (BMT only). The effects of supervised exercise
and cilostazol combined did not fit into a multiplicative
model (P .383), thus indicating that the beneficial effects
of combined adjuvant therapy are likely to be only additive.
With regard to claudication distance, no significant im-
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Fig. Change in absolute claudication distance over 6 months by
treatment group. *Wilcoxon signed rank test. BMT, best medical
therapy alone; SE, BMT  supervised exercise; CIL, BMT 
cilostazol; SE  CIL, BMT  supervised exercise  cilostazol;
ACD, absolute claudication distance.provement was observed in ICD or ACD in subjects remain-ing solely onBMT(median [IQR] ICDat baseline, 3months,
and 6 months: 59 m [48-72 m], 73 m [46-80 m], and 64 m
[47-77 m]; P  .678; ACD: 94 m [79-162 m], 137 m
[94-175 m], and 120 m [91-160 m]; P  .635); however,
significant improvements were observed in ICD and ACD
with both supervised exercise (median [IQR] ICD at base-
line, 3 months, and 6 months: 60 m [45-95 m], 110 m
[66-194 m], and 127 m [62-180 m]; P .01; ACD: 99 m
[81-241 m], 218 m [122-339 m], and 206 m [122-369 m];
P .002) and cilostazol (median [IQR] ICD at baseline,
3 months, and 6 months: 68 m [48-76 m], 126 m
[74-194 m], and 149 m [95-213 m]; P  .001; ACD:
116 m [76-229 m], 226 m [105-335 m], and 204 m
[118-405 m]; P  .001). ANOVA indicates that neither
exercise (P  .488) nor cilostazol (P  .090) affords any
significant improvement in terms of ICD when com-
pared with BMT alone. However, there were significant
benefits in terms of ACD with both supervised exercise
( P  .037) and cilostazol (P  .005) (Fig). As with
ABPI, the effect on ACD of supervised exercise and
cilostazol combined is likely to be additive, because it did
not fit into a multiplicative model (P  .362).
Thrombin generation. None of the treatment groups
demonstrated any significant change in resting TAT levels
over the 6-month study period (median [IQR] TAT levels
at baseline, 3 months, and 6months—BMT alone: 1.2 g/L
[0.6-3.2 g/L], 1.5 g/L [1.2-3.9 g/L], and 2.4
g/L [1.5-4.3 g/L]; P  .123; supervised exercise:
1.2 g/L [0.1-2.5 g/L], 0.75 g/L [0.3-2.6 g/L],
and 1.1 g/L [0.1-3.3 g/L]; P  .929; cilostazol: 1.1
g/L [0.1-2.1 g/L], 0.8 g/L [0.4-2.1 g/L], and
1.0 g/L [0.1-1.7 g/L]; P  .65; Wilcoxon test).
Subjects randomized to receive cilostazol demonstrated
a significant increase in resting PF12 levels at 6 months
(median [IQR] PF12 levels at baseline, 3 months, and
6 months: BMT alone: 0.7 nmol/L [0.6-1.0 nmol/L], 0.7
nmol/L [0.6-1.0 nmol/L], and 0.7 nmol/L [0.6-1.1
nmol/L]; P .916; supervised exercise: 0.8 nmol/L [0.6-
1.0 nmol/L], 0.8 nmol/L [0.7-1.3 nmol/L], and 0.9
nmol/L [0.7-1.3 nmol/L]; P  .083; cilostazol: 0.6
nmol/L [0.6-0.7 nmol/L], 0.8 nmol/L [0.6-1.3 nmol/L],
and 1.0 nmol/L [0.6-1.3 nmol/L]; P  .002; Wilcoxon
test). However, subjects taking cilostazol had significantly
lower resting baseline PF12 levels than subjects who did
not receive cilostazol (P  .004; Mann-Whitney U test).
TAT and PF12 showed no correlation with ABPI, ICD,
or ACD at baseline or at 6 months.
Fibrinolysis. There were no significant differences
in baseline values or changes over 6 months in measured
t-PA antigen (median [IQR] t-PA antigen levels at base-
line, 3 months, and 6 months—BMT alone: 6.4 ng/L
[3.5-10.5 ng/L], 6.2 ng/L [2.9-8.8 ng/L], and 6.7
ng/L [4.0-9.0 ng/L]; P .779; supervised exercise: 4.5
ng/L [2.9-6.5 ng/L], 4.9 ng/L [3.2-6.0 ng/L], and
5.3 ng/L [3.4-7.5 ng/L]; P  .084; cilostazol: 4.5
ng/L [2.9-5.6 ng/L], 3.8 ng/L [1.9-5.6 ng/L], and
3.8 ng/L [2.6-5.8 ng/L]; P  .717; Wilcoxon test),
t-PA activity (virtually all 0.1 U/mL), or PAI-1 antigen
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and 6months—BMT alone: 24.5 ng/L [15.3-44.8 ng/L],
19.5 ng/L [12.3-42.0 ng/L], and 28.0 ng/L [14.3-42.0
ng/L]; P .889; supervised exercise: 18.0 ng/L [1.0-34.8
ng/L], 17.0 ng/L [1.8-30.3 ng/L], and 22.0 ng/L [1.0-
33.0 ng/L]; P  .553; cilostazol: 21.5 ng/L [3.3-32.5
ng/L], 13.5 ng/L [2.0-33.5 ng/L], and 20.0 ng/L [1.5-
32.8 ng/L]; P  .55; Wilcoxon test). Furthermore, there
was no correlation between these markers and ABPI, ICD,
or ACD.
DISCUSSION
These data confirm that, after 6 months, BMT 
supervised exercise and BMT  cilostazol are superior to
BMT alone in terms of improving ACD. There was no
statistical difference between BMT  supervised exercise
and BMT  cilostazol in terms of ACD, and the effect of
combined treatment seems to be additive rather than mul-
tiplicative. The 64% improvement in ACD observed after 6
months of BMT cilostazol is comparable to that reported
in previous randomized controlled trials (35% and 109%).9
In contrast, the 40% improvement in ACD after 6 months
of BMT supervised exercise is rather lower than improve-
ments previously reported in meta-analyses of randomized
controlled trials.7,8 Although this discrepancy may be a
consequence of the design of the exercise program, in pilot
and other clinical studies, our exercise program has been
validated for use in subjects with IC. Monitoring of maxi-
mal heart rates and repetitions performed at each exercise
station in the circuit demonstrated a significant training
effect over the 12-week program. We therefore believe that
the intensity of the exercise in the program was adequate.
We assume that the sample size is the reason why significant
improvements were not observed after supervised exercise.
It is important to note, however, that the treatment effects
Table II. Demographic details, medication, and disease se
Variable BMT Supervised ex
No. subjects 9 9
Age (y) 67 (63.5-74) 66 (63-7
Sex (M:F) 7:2 7:2
Smoking status
Current smoker 3 4
Ex-smoker 5 4
Never smoker 1 1
Diabetes 2 1
Medication
Antiplatelet agent 9 9
Statin 8 9
Antihypertensive 8 8
ACE inhibitor 5 5
Baseline treated lipid profile
Total cholesterol (mmol/L) 6.0 (4.5-6.7) 4.1 (3.7-4
Triglycerides (mmol/L) 1.6 (1.0-2.0) 2.6 (1.7-3
INEXACT, INtermittent Claudication, EXercise, and Cilostazol Trial; BMT
Figures represent numbers of subjects or median (interquartile range) wher
*Analysis of variance.
†Fisher exact test.of supervised exercise in our study were calculated over andabove the effect observed with remaining solely on BMT
(most claudication exercise trials do not do this). Because 6
months of medical therapy improved ACD by 9% in our
study, this therefore further reduces the treatment effect of
supervised exercise.
In addition to improvements in ACD, subjects receiv-
ing 6 months of BMT  supervised exercise or BMT 
cilostazol, but not BMT only, also enjoyed significant
increases in their ICD on paired statistical analysis. When
compared with BMT only, supervised exercise and cilosta-
zol both resulted in significant improvements in ABPI of
18% and 13%, respectively. Again, these results are consis-
tent with previous studies of cilostazol13 and exercise ther-
apy.14 Overall, the evidence for exercise-induced increases
in blood flow in claudicants is limited and inconsistent, and
it is likely that mechanisms other than increases in collateral
blood flow account for most symptomatic and functional
improvements seen with exercise programs (such as im-
provements in microcirculation, muscle metabolism, walk-
ing economy, and blood viscosity). Although our study
showed significant (albeit small) improvements in ABPI
with exercise and cilostazol when compared with BMT
only, much of this improvement became apparent only
because of the deterioration of ABPI in subjects random-
ized to BMT only, presumably as a result of disease pro-
gression. Thus, although not powered to look at ICD,
ACD, and ABPI as end points, this substudy has produced
some clinical and hemodynamic results that are consistent,
qualitatively and quantitatively, with those that have been
reported in previous trials and might be expected from the
full INEXACT trial.
This substudy of INEXACT has demonstrated that,
unlike balloon angioplasty, which has previously been
shown to ameliorate the procoagulant diathesis in patients
with IC,6 treatment with supervised exercise or cilostazol,
y of subjects enrolled onto the INEXACT trial
Cilostazol Supervised exercise  cilostazol P value
9 7
58 (52-71) 72 (63-74) .196*
8:1 5:2
3 2 NS†
6 4 NS†
0 1 NS†
3 1 NS†
9 7 NS†
9 7 NS†
6 6 NS†
3 4 NS†
4.5 (3.4-4.9) 4.3 (4.0-6.0) 0.059*
2.0 (1.7-3.4) 1.5 (1.2-2.0) 0.311*
medical therapy;NS, not significant;ACE, angiotensin-converting enzyme.
opriate.verit
ercise
1)
.7)
.0)
, best
e appreither singly or in combination, despite resulting in symp-
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fect on the subjects’ resting prothrombotic and hypofi-
brinolytic state. We hypothesize that this finding is because
neither obtunds the IRI associated with walking. It is
possible, of course, that as supervised exercise and cilostazol
both resulted in a small improvement in ABPI, this also
could have resulted in a small improvement in the proco-
agulant diathesis, but because of a type II error, this was not
detected in this study. Therefore, the results need to be
interpreted with some degree of caution. Regardless of this,
it is clear that these treatments do not produce the previ-
ously published hemostatic improvements observed with
angioplasty.
To our knowledge, this is the first study to examine the
effects of cilostazol and the second to examine the effect of
supervised exercise on coagulation in subjects with IC.
Although evidence exists for training-induced adaptations
Table III. Mean ratios (standard deviation) of ankle-
brachial pressure index, initial and absolute claudication
distance compared with baseline and at 6 months for each
treatment group, and the overall effect at 6 months
compared with receiving no adjuvant treatment
Treatment group
Change from
baseline to
6 mo
Overall
effect by
6 mo*
P
value†
ABPI
BMT 0.93 (0.11)
BMT  exercise 1.09 (0.11) 1.17
BMT  cilostazol 1.05 (0.13) 1.13
BMT  cilostazol  exercise 1.30 (0.24) 1.40
No exercise 0.99 (0.13)
All exercise 1.17 (0.19) 1.18 .001
No cilostazol 1.01 (0.14)
All cilostazol 1.14 (0.21) 1.13 .003
ICD
BMT 1.23 (0.73)
BMT  exercise 2.22 (2.71) 1.80
BMT  cilostazol 3.34 (4.23) 2.72
BMT  cilostazol  exercise 3.84 (3.62) 3.12
No exercise 2.28 (3.14)
All exercise 2.93 (3.14) 1.29 .488
No cilostazol 1.72 (1.99)
All cilostazol 3.56 (3.86) 2.07 .090
ACD
BMT 1.09 (0.34)
BMT  exercise 1.45 (0.80) 1.33
BMT  cilostazol 1.69 (0.59) 1.55
BMT  cilostazol  exercise 2.58 (1.39) 2.37
No exercise 1.39 (0.56)
All exercise 1.94 (1.20) 1.40 .037
No cilostazol 1.27 (0.62)
All cilostazol 2.08 (1.68) 1.64 .005
ABPI, Ankle-brachial pressure index; BMT, best medical therapy alone; No
exercise, BMT alone and BMT  cilostazol; All exercise, BMT  supervised
exercise and BMT  supervised exercise  cilostazol; No cilostazol, BMT
alone and BMT  supervised exercise; All cilostazol, BMT  cilostazol and
BMT  supervised exercise  cilostazol.
*Compared with receiving no treatment.
†General Linear Model.for some markers of coagulation potential in healthy indi-viduals, the effect of exercise training on thrombin produc-
tion in subjects with peripheral arterial disease has not been
fully evaluated, and in subjects with coronary heart disease,
the data are equivocal.15 With regard to fibrinolysis and
exercise training, only one nonrandomized study in periph-
eral arterial disease has assessed the effect of training on
fibrinolysis, and it found that a 6-month training program
improved the resting fibrinolytic state.16 Our study did not
show an improvement in fibrinolysis as a result of exercise
training. To our knowledge, this study is also the first to
examine the clinical, hemodynamic, and coagulation effects
of combined adjuvant therapy with BMT  supervised
exercise  cilostazol.
What is the longer-term clinical significance of symp-
tomatic improvement, but without the amelioration of IRI
and the procoagulant diathesis seen after supervised exer-
cise and/or cilostazol adjuvant treatment, when compared
with the effects of balloon angioplasty and, presumably,
surgery?6,17 It is possible that by obtunding IRI and, thus,
attenuating the resting and postexercise prothrombotic
state, balloon angioplasty and, presumably, surgery, but
not supervised exercise and/or cilostazol, have the poten-
tial to improve morbidity and mortality from thrombotic
events in this group of patients in the longer term. If so,
there would be a strong argument for attempting, where
possible, to revascularize the ischemic limbs of patients with
IC either by surgical or endovascular means.
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Based on the findings of this study and a previous one,1Hobbs
et al have proposed a novel idea: that angioplasty or surgery for
infrainguinal arterial occlusive disease might reduce cardiovascular
morbidity and mortality to a greater degree than exercise rehabil-
itation or the pharmacologic agent cilostazol, or both. In fact, they
suggest that exercise may actively increase the risk of events such as
myocardial infarction because the ischemia–reperfusion injury in
leg muscle associated with walking contributes to atherothrom-
botic morbidity and mortality.
These conclusions are based on observations in their current
study that neither exercise rehabilitation nor cilostazol had any
beneficial effects on thrombin generation or fibrinolysis, as well as
observations from the previous study that patients treated with
angioplasty experienced significantly increased fibrinolysis and re-
duced thrombin generation.1 Indeed, there is also literature show-
ing that walking, by promoting ischemia–reperfusion in leg mus-
cles, is associated with increased inflammation and that this in turn
may promote progression of atherosclerotic disease.2,3
Taking these findings together, should we conclude that walk-
ing is bad for patients with claudication? Should we encourage
more invasive treatments on the supposition that they are better,
that they protect our patients from myocardial infarction and
stroke? Some caution is in order.
Numerous trials and studies have shown that pain-free and
maximal walking distances in patients with claudication can be
increased by exercise rehabilitation.4 Population studies such as the
Honolulu Heart Study showed that individuals who walk more
have a lower incidence of myocardial infarction compared with
those who walk less.5 The studies by Hobbs et al, although
randomized, are small, with50 patients in each. It is possible that
the lack of effects of exercise therapy on thrombin generation and
fibrinolytic activity are related to a type II error from the small
sample size. Our group completed two studies on patients withtients with claudication was directly correlated with physical activ-
ity level, and that a 6-month exercise regimen improved fibrinolysis
in these patients.6,7
Nonetheless, the ideas of Hobbs et al deserve serious consid-
eration, and further study is clearly warranted. Perhaps the vascular
community should embrace invasive therapy for claudication not
only to improve walking ability and functional status but also to
reduce cardiovascular morbidity and mortality.
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